21/03/2014 - Letter of recommendation of Holvita Organic Liquid Colostrum from Barts and The London Queen Mary’s School of Medicine and Dentistry
It is a pleasure to write in support of the Holvita Organic Colostrum. We took part in a clinical trial of this medication in a group of patients with advanced cirrhosis. We found the Holvita Colostrum to be well tolerated with a very good safety profile - no adverse events were observed in patients taking colostrum. Many patients commented on an improvement in their general well being during the study. In summary data from a small scale clinical trial indicated that Holvita Organic Colostrum is safe, even in patients with very severe underlying illness.Yours sincerely
Graham R Foster
Professor of Hepatology
10/05/2012 - HOLVITA™ LIQUID COLOSTRUM PILOT STUDY UPDATE
Queen Mary University of London in conjunction with Barts Health are conducting clinical trials with Holvita colostrum in patients with
advanced liver disease.
The trial is proceeding satisfactory and this brand of colostrum appears to be safe and well tolerated.
Graham R Foster PhD FRCP
Profesor of Hepatology
The Blizzard Institute
4 Newark Street
London E1 4AT
26/06/2011 - HOLVITA™ LIQUID COLOSTRUM PILOT STUDY
We are pleased to announce that holvita™ liquid colostrum is tested in a double blinded cross-over study at Barts Hospitals in London.
The double blinded, cross-over clinical study to determine the value of the cold filtered liquid colostrum holvita™ to chronically ill people with hepatitis c has started.The study will determine the potential value of holvita™ liquid colostrum on patients with hepatitis c related liver cirrhosis and will look at the effect of this colostrum on viral load, the blood picture and quality of life.
Lead Investigator is Professor Graham Foster, Professor of Hepatology at Barts and The London and Queen Marys University of London.
The evaluation of this pilot study will take place throughout January 2012 and the results will be published in first quarter of 2012.
26/02/2011 - Holvita™ Liquid Colostrum price change
There were changes made to the prices of our colostrum liquid, please note the new prices in our shop section before purchasing.
holvita colostrum team
03/09/2010 - Holvita™ Liquid Colostrum pilot study
There now exists a respectable body of anecdotal evidence to suggest that the cold-filtered liquid colostrum holvita™ can be of benefit in a number of disorders. A number of chronically ill people with hepatitis c, including those with liver cirrhosis, have claimed a significant improvement in their health and general wellbeing while taking holvita™ liquid colostrum. To determine whether these anecdotal reports are representative a pilot study will begin in the latter part of 2010, involving 20 patients with hepatitis C related liver cirrhosis. Contracts have been signed between CPD Ltd and Barts and the London Hospital NHS Trust to determine the potential value of holvita™ liquid colostrum on patients with hepatitis c related liver cirrhosis. The study will look at the effects of this colostrum on the viral load, the blood picture and quality of life. The Lead Investigator will be Professor Graham Foster, Professor of Hepatology at The Centre for Digestive Diseases, Barts and The London School of Medicine and Dentistry.
We will keep you informed on the ongoing trial, the results will be published once available on our website.
Thank you very much
CPD Ltd. Holvita™ Colostrum team
Price changes - 14/12/08
Due to recent heavy currency fluctuations and the fall in value of Stirling we are forced as of 1st of January 2009 to increase the prices of our liquid and capsule colostrum products. Prices for our skin products will remain unchanged.
holvita colostrum team